Johnson & Johnson (JNJ) Shares Sold by Godshalk Welsh Capital Management Inc.
Godshalk Welsh Capital Management Inc. lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 6.4% during the third quarter, Holdings Channel reports. The institutional investor owned 14,900 shares of the company’s stock after selling 1,025 shares during the quarter. Johnson & Johnson accounts for approximately 1.9% of Godshalk Welsh Capital Management Inc.’s portfolio, making the stock its 6th largest position. Godshalk Welsh Capital Management Inc.’s holdings in Johnson & Johnson were worth $1,937,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in JNJ. Harding Loevner LP acquired a new position in shares of Johnson & Johnson in the second quarter valued at approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its position in shares of Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the last quarter. Mountain Capital Investment Advisors Inc acquired a new position in shares of Johnson & Johnson in the second quarter valued at approximately $124,000. Shine Investment Advisory Services Inc. acquired a new position in shares of Johnson & Johnson in the second quarter valued at approximately $177,000. Finally, Lenox Wealth Management Inc. grew its position in shares of Johnson & Johnson by 1.7% in the second quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock valued at $193,000 after purchasing an additional 24 shares during the last quarter. 66.38% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Johnson & Johnson (NYSE:JNJ) opened at $128.82 on Monday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12. The stock has a market capitalization of $345,611.47, a P/E ratio of 17.65, a P/E/G ratio of 2.11 and a beta of 0.77. Johnson & Johnson has a 12 month low of $120.95 and a 12 month high of $148.32.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.61%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 861.54%.
In related news, VP Paulus Stoffels sold 155,342 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the completion of the sale, the vice president now directly owns 357,906 shares in the company, valued at $46,477,673.16. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 0.19% of the company’s stock.
Several equities analysts have recently commented on JNJ shares. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 target price on the stock in a research report on Tuesday, January 23rd. Credit Suisse Group set a $154.00 target price on Johnson & Johnson and gave the company a “hold” rating in a research report on Monday, January 22nd. Stifel Nicolaus upped their target price on Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a research report on Wednesday, January 24th. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $160.00 target price (up previously from $155.00) on shares of Johnson & Johnson in a research report on Friday, January 12th. Finally, Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, January 9th. Four research analysts have rated the stock with a sell rating, nine have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $146.26.
ILLEGAL ACTIVITY NOTICE: This story was reported by Watch List News and is the property of of Watch List News. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.watchlistnews.com/johnson-johnson-jnj-shares-sold-by-godshalk-welsh-capital-management-inc/1908704.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.